Is DPP4 inhibition a comrade or adversary in COVID-19 infection

被引：25

作者：

Dalan, Rinkoo ^{[1
,2
]}

机构：

[1] Tan Tock Seng Hosp, Singapore, Singapore

[2] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2020年 / 164卷

基金：

英国医学研究理事会;

关键词：

COVID-19; DPP-4; inhibitors;

D O I：

10.1016/j.diabres.2020.108216

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Hypertension and Diabetes are the most common comorbid conditions in patients with COVID-19 and has been shown to adversely impact prognosis globally. It has been shown that hyperglycemia is one of the factors that increases the risk of poor outcomes in these patients. These patients are usually on multiple medications and recently a series of discussion on how Dipeptidyl peptidase 4 inhibitors (DPP4i) may be beneficial in these patients has been presented. This commentary presents a nuanced debate on why the DPP4i may not be beneficial in COVID-19 and that caution needs to be addressed in making any judgements until real world data is available. (C) 2020 Elsevier B.V. All rights reserved.

引用

页数：3

共 20 条

[1]

Arce Victor M., 2021, CELLULAR AMP MOL IMM, V18, P513, DOI [10.1038/s41423-020-00616-1, DOI 10.1038/S41423-020-0402-2, DOI 10.1038/S41423-020-0424-]

[2] Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States [J].

Bode, Bruce ;

Garrett, Valerie ;

Messler, Jordan ;

McFarland, Raymie ;

Crowe, Jennifer ;

Booth, Robby ;

Klonoff, David C. .

JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2020, 14 (04) :813-821

[3] Endocrine and metabolic link to coronavirus infection [J].

Bornstein, Stefan R. ;

Dalan, Rinkoo ;

Hopkins, David ;

Mingrone, Geltrude ;

Boehm, Bernhard O. .

NATURE REVIEWS ENDOCRINOLOGY, 2020, 16 (06) :297-298

[4]

Dominguez-Erquicia P, 2020, EUR HEART J, DOI [10.1093/eurheartj/ehaa393, DOI 10.1093/EURHEARTJ/EHAA393]

[5] The CD26/DPP4-inhibitor vildagliptin suppresses lung cancer growth via macrophage-mediated NK cell activity [J].

Jang, Jae-Hwi ;

Janker, Florian ;

De Meester, Ingrid ;

Arni, Stephan ;

Borgeaud, Nathalie ;

Yamada, Yoshito ;

Bazo, Ignacio Gil ;

Weder, Walter ;

Jungraithmayr, Wolfgang .

CARCINOGENESIS, 2019, 40 (02) :324-334

[6]

Jiang M, J INFECT DIS

[7] CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation [J].

Jungraithmayr, Wolfgang ;

De Meester, Ingrid ;

Matheeussen, Veerle ;

Baerts, Lesley ;

Arni, Stephan ;

Weder, Walter .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2012, 41 (05) :1166-1173

[8] DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice [J].

Kawasaki, Takeshi ;

Chen, Weiguo ;

Htwe, Yu Maw ;

Tatsumi, Koichiro ;

Dudek, Steven M. .

AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2018, 315 (05) :L834-L845

[9] Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients [J].

Krijnen, Paul A. J. ;

Hahn, Nynke E. ;

Kholova, Ivana ;

Baylan, Umit ;

Sipkens, Jessica A. ;

van Alphen, Floris P. ;

Vonk, Alexander B. A. ;

Simsek, Suat ;

Meischl, Christof ;

Schalkwijk, Casper G. ;

van Buul, Jaap D. ;

van Hinsbergh, Victor W. M. ;

Niessen, Hans W. M. .

BASIC RESEARCH IN CARDIOLOGY, 2012, 107 (01)

[10]

Li Yu, 2020, CELL PRESS, DOI [10.2139/ssrn.3570560, DOI 10.2139/SSRN.3570560]

← 1 2 →